The efficacy of FMD vaccine reduced non-structural proteins with a mAb against 3B protein.
A monoclonal antibody, 3BIgG, against the prokaryotically expressed foot-and-mouth disease virus (FMDV) non-structural protein (NSP) 3B was obtained. The 3BIgG-sepharose conjugant (3BmAb-6BFF) was prepared by adding the purified 3BIgG into epoxy-activated sepharose 6BFF, incubating with the inactivated FMDV, and then removing the sepharose by centrifugation. The vaccine was made from the supernatant emulsified with oil-adjuvant ISA206. Ten guinea pigs, 26 pigs and six cattle were vaccinated, and a vaccination control group was included without treatment with 3BmAb-6BFF. After 28 days, 9/10 pigs challenged with FMDV were protected, this result was the same as the control group, indicating that the vaccine potency was not reduced after treatment with 3BmAb-6BFF. The other animals were vaccinated weekly for nine weeks, and serum samples were collected to detect 3ABC-antibody titers. The results showed that 3ABC-antibody production was delayed and the positive antibody rates were lower when vaccination was carried out using vaccines treated with 3BmAb-6BFF compared with untreated vaccines. The findings of this study suggest that it is possible to reduce NSPs using a mAb-sepharose conjugant in FMD vaccines without reducing their efficacy.
Key Laboratory of Animal Virology of the Ministry of Agriculture, National Foot-and-Mouth Disease Reference Laboratory of China, State Key Laboratory of Veterinary Etiologic Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China. lidongpaul@yahoo.com.cn
Dong
D
Li
Zai-Xin
ZX
Liu
Pu
P
Sun
Yong-Liang
YL
Li
Zeng-Jun
ZJ
Lu
Mei-Na
MN
Tian
Ying-Li
YL
Chen
Bao-Xia
BX
Xie
Hui-Fang
HF
Bao
Yuan-Fang
YF
Fu
Yi-Mei
YM
Cao
Ping-Hua
PH
Li
Xin-Wen
XW
Bai
Jia-Chuan
JC
Sun
Jian-Hong
JH
Guo
Xiang-Tao
XT
Liu
Qing-Ge
QG
Xie
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D002417:Cattle / Q000276:immunology / Q000821:virology; D005536:Foot-and-Mouth Disease / Q000276:immunology / Q000517:prevention & control*; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology*; D006168:Guinea Pigs / Q000276:immunology / Q000821:virology; D013552:Swine / Q000276:immunology / Q000821:virology; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use; D017361:Viral Nonstructural Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D017361:Viral Nonstructural Proteins; D014765:Viral Vaccines